Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up?

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1053-1057

  Petrausch, U ^a   Samaras, P ^a   Veit Haibach, P ^a   Tschopp, A ^b   Soyka, J D ^a   Knuth, A ^a   Hany, T F ^a   Mischo, A ^a   Renner, C ^a   Schaefer, N G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Follow up; Hodgkin's lymphoma; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953334559     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp519     Document Type: Article

References (14)

1. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004; 52: 19-32.
2. DeVita VT, Bonadonna G. The history of the chemotherapy of Hodgkin's disease. In Mauch PM, Armitage JO, Diehl V et al. (eds), Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins 1999; p. 9-22.
3. Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 108-109.
4. Brusamolino E, Bacigalupo A, Barosi G et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009; 94: 550-565.
5. Fletcher JW, Djulbegovic B, Soares HP et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508.
6. Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-130.
7. Zinzani PL, Stefoni V, Tani M et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009; 27: 1781-1787.
8. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease.International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
9. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
10. Cheson B. The case against heavy PETing. J Clin Oncol 2009; 27: 1742-1743.
11. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9: 1196-1203.
12. Oh YK, Ha CS, Samuels BI et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999; 210: 483-486.
13. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006; 17: 909-913.
14. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112(10): 3989-3994.